Lilly to sell obesity drugs directly on Hims & Hers site

What happened

Eli Lilly agreed to let Hims & Hers sell its obesity drugs Zepbound and Foundayo directly through the telehealth platform. Previously, customers had to leave Hims & Hers and use LillyDirect to buy them. Hims & Hers also agreed not to sell compounded versions or knockoffs of Lilly’s obesity medicines.

Confirmed

Global impact / market context

A direct purchase route removes a step for Hims & Hers customers, which Lilly’s US president said could reduce customer drop-off. The deal also ties access to Lilly medicines to an agreement against selling compounded copies, potentially shifting sales toward Lilly’s branded products.

Analyst inference

The change places Lilly on Hims & Hers alongside Novo Nordisk, whose Wegovy and Ozempic have been sold there since March. Lilly’s self-pay prices remain aligned with LillyDirect: $149 monthly for Foundayo and $299 for Zepbound, according to the article.

Confirmed

What to watch

1. Watch whether direct access through Hims & Hers leads to more Lilly prescriptions or sales; the article reports the deal but gives no expected volume or revenue. Analyst inference
2. Check whether Hims & Hers continues to honor its agreement not to sell compounded Lilly medicines or knockoffs, as this condition is part of the deal. Confirmed
3. Compare Lilly’s self-pay prices with the prices offered through its own LillyDirect service; the article says both Foundayo and Zepbound prices match there. Confirmed

Evidence

• Original source link unavailable